Categories: News

PolyPid to Present at First World Association Against Infection in Orthopaedics and Trauma Congress

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Virtual Presentation to be led by PolyPid Co-Founder and CSO on August 28, 2021

PETACH TIKVA, Israel, Aug. 17, 2021 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes, announced today that its Co-Founder and Chief Scientific Officer Dr. Noam Emanuel, will deliver a virtual presentation at the first World Association against Infection in Orthopaedics and Trauma (WAIOT) Congress on August 28, 2021.

The virtual presentation will be a part of the Septic Non-Union and Bone Loss Management session. The presentation details can be found below:

Location: Room 3
Lecture Number: 0 41
Time: 16:11 – 16:16 CEST
Presentation Title:
    Improved Healing of Gustilo Type IIIA and IIIB Open Long Bone Fractures Treated with Local Biodegradable Prolonged Release Antibiotic Formulated Bone Graft During the First Surgical Intervention Post-Surgery: A Prospective, Randomized Clinical Trial
Presenter:
    Dr. Noam Emanuel, PolyPid

WAIOT is the first and the largest worldwide scientific association, focused on bone, joints, biofilms- and implant-related infections. The event will be attended by 1,700 members coming together virtually from 101 countries.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharmaceutical company focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).

For additional company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its ongoing clinical trials, plans to use the guidance provided by the FDA to progress with its SHIELD I program, the timing of top-line results of the SHIELD I trial, and the size and design of the SHIELD I trial. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on March 5, 2021. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Corporate Contact
PolyPid, Ltd.
Dikla Czaczkes Akselbrad
EVP & CFO
+972-747195700

Investor Contact
Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

Media Contact
Nechama Feuerstein
551-444-0784
Nechama.Feuerstein@finnpartners.com 

Staff

Recent Posts

Maria Ansari, MD, FACC, named to Modern Healthcare’s list of 50 Most Influential Clinical Executives

Co-CEO of The Permanente Federation and leader of multiple Permanente Medical Groups at Kaiser Permanente,…

9 hours ago

Dignify Therapeutics Announces Jeff Welch as Chief Operating Officer

RESEARCH TRIANGLE PARK, N.C., June 12, 2025 /PRNewswire/ -- Dignify Therapeutics (Dignify), a pharmaceutical and medical…

9 hours ago

Transforming Communication in the Workplace and Beyond: Glodean Champion Launches “The Process to LOVE™” – A Revolutionary Communication Framework for Human-Centered Leadership

CHICAGO, June 12, 2025 /PRNewswire/ -- Workplace miscommunication costs businesses an estimated $1.2 trillion annually and…

9 hours ago

THE MERCY SHIPS to Launch Exclusively on Angel.com and the Angel App. First Three Episodes to Stream Free of Charge

Step aboard the world's largest civilian-run hospital ships and witness stories of compassion, courage, and…

9 hours ago

LabConnect Selects Deloitte to Streamline Financial and Business Operations

JOHNSON CITY, Tenn., June 12, 2025 /PRNewswire/ -- LabConnect, a leading provider of global central…

15 hours ago

BUDS Technology Transforms Senior Care with AKSSI Virtual Nurse Assistant

ROSWELL, Ga., June 12, 2025 /PRNewswire/ -- Buds Technology, a leading innovator in healthcare solutions, has…

15 hours ago